TSB and CR Pharma partner for COVID-19 antibody therapy in China

TSB Therapeutics has entered a collaboration with China Resources Pharmaceutical Commercial Group (CR Pharma) for the commercialisation of an antibody therapy, amubarvimab/romlusevimab combination, for COVID-19 in China.

These two non-competing SARS-CoV-2 monoclonal neutralising antibodies (mAbs) are obtained from convalesced COVID-19 patients.

Brii Bio, the company that owns TSB Therapeutics, developed the combination therapy in partnership with Tsinghua University and the 3rd People’s Hospital of Shenzhen. 

Under the terms of the collaboration, the parties will expedite the stockpiling, channel distribution, and offer access to hospitals for the long-acting neutralising mAbs. The companies are partnering to guarantee timely delivery of the therapy, to support COVID-19 prevention, and control efforts in the region.

The companies will also explore other new collaboration opportunities to facilitate extended access for the amubarvimab-romlusevimab combination in China.

Brii Bio Greater China president and general manager, Rogers Luo, commented: “In 2019, Brii Bio started a strategic partnership with China Resources Group to jointly build an integrated industrial chain of life sciences.

“This strong and strategic partnership and unique operating model enables Brii Bio to rapidly expand access to our amubarvimab/romlusevimab combination, to help more COVID-19 patients in China, and we look forward to exploring in-depth collaborative efforts with China Resources Pharmaceutical Group down the line for the long-term benefit of patients and the healthcare community.”

Lina Adams